The global keytruda market is anticipated to grow at a significant CAGR during the forecast period (2022-2028).Keytruda is an immunotherapy drug that works with the immune system to treat specific malignancies. It may be used in adults and children of 12 years of age and above with stage IIB, stage IIC, or stage III melanoma to help prevent melanoma from returning and cancer-containing lymph nodes have been removed by surgery (advanced melanoma). Additionally, when lung cancer has progressed (advanced NSCLC) and is a form termed “nonsquamous” and the tumor does not contain an aberrant “EGFR” or “ALK” gene, then keytruda can be utilized as the first treatment with the chemotherapy medications pemetrexed and platinum. The rising prevalence of various types of cancer globally is a primary factor driving the keytruda market.
(Get 15% Discount on Buying this Report)
Get Sample Copy of Keytruda at: https://orionmarketreports.com/request-sample/?id=103512&submit=Request+Sample%0D%0A
The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, in order to stay competitive in the market. For instance-
- In January 2022, Gilead Sciences, Inc. announced that it has entered into two clinical trial collaboration and supply agreements with Merck (known as MSD outside of the US and Canada) to evaluate the combination of Gilead’s Trop-2 targeting antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan-hziy) and Merck’s anti-PD-1 therapy keytruda (pembrolizumab) in first-line meta (NSCLC). Merck will fund a global Phase-3 clinical trial of Trodelvy in combination with keytruda as first-line therapy for patients with metastatic NSCLC as part of this collaboration.
- In October 2021, the USFDA approved Merck’s anti-PD-1 therapy, keytruda, in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (Combined Positive Score [CPS] 1), as determined by an USFDA-approved test. The approval is based on the KEYNOTE-826 Phase-3 study, which compared keytruda with chemotherapy (paclitaxel plus cisplatin or paclitaxel plus carboplatin), with or without bevacizumab, against chemotherapy alone, with or without bevacizumab.
A full report of Global Keytruda Market is available at: https://orionmarketreports.com/keytruda-market/103512/
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Distribution Channel
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
· Competitive Landscape- Amgen Inc., GlaxoSmithKline Plc, AstraZeneca plc, Bristol Myers Squibb, and Merck & Co. Inc., among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Keytruda Market Report by Segment
By Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- Others
About Us:
Orion Market Reports (OMR) endeavors to provide an exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and the most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
